Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-12-22

FDA Approved: TAZAROTENE — Original Application (Mayne Pharma)

View source ↗

Summary

FDA approved Mayne Pharma's original ANDA for tazarotene, enabling the generic topical retinoid product to enter the market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAZAROTENE (TAZAROTENE)

Snippet

ORIG AP for TAZAROTENE (TAZAROTENE)